Brexit Could Make UK A 'Second-Tier State' For Innovative New Drugs, Business Committee Warns

 
• By Ian Schofield

A report from the UK House of Commons business committee on its inquiry into the impact of Brexit on the pharma sector has flagged up the multiple challenges facing companies and regulators.

EU_UK
A UK parliamentary committee has outlined the drawbacks of Brexit for the pharma sector

More from Approvals

More from Product Reviews